Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies

Citation
T. Kawatani et al., Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies, EUR J HAEMA, 67(1), 2001, pp. 45-50
Citations number
19
Categorie Soggetti
Hematology,"Cardiovascular & Hematology Research
Journal title
EUROPEAN JOURNAL OF HAEMATOLOGY
ISSN journal
09024441 → ACNP
Volume
67
Issue
1
Year of publication
2001
Pages
45 - 50
Database
ISI
SICI code
0902-4441(200107)67:1<45:IOHVIA>2.0.ZU;2-G
Abstract
Hepatitis virus infection through virus reactivation has a high risk of mor tality in patients with hematological malignancies receiving chemotherapy. We examined the incidence of both hepatitis B virus (HBV) and hepatitis C v irus (HCV) infection and severe liver dysfunction (alanine aminotransferase > ten times the normal upper limit and total bilirubin >5 mg/dl) during ch emotherapy in 268 patients with hematological malignancies. Eight patients (3.0%) were infected with HBV and 22 patients (8.2%) were infected with HCV . One patient (0.4%) was infected with both HBV and HCV. HBV- or HCV-infect ed patients showed severe liver dysfunction at a significantly higher incid ence than non-infected patients (11/31 (35.5%) vs. 0/237 (0%), p <0.0001). Furthermore, the incidence of severe liver dysfunction in HBV-infected pati ents was significantly higher than in HCV-infected patients (6/8 (75.0%) vs . 4/22 (18.2%), p <0.01). Three of eight HBV-infected patients were initial ly negative for hepatitis B surface antigen (HBsAg) by latex agglutination and became positive for HBsAg during chemotherapy. Furthermore, all three p atients developed severe liver dysfunction and two developed fatal fulminan t hepatitis. From an examination of the original stock of serum samples bef ore chemotherapy, two patients were found to be positive for HBV-DNA by pol ymerase chain reaction (PCR). Although post-transfusion HBV infection was s uspected in the one remaining patient, the cause of HBV infection could not be clarified due to the impossibility of examination in blood donors. Sinc e HBV-infected patients develop severe liver dysfunction at a higher incide nce than either patients not infected with virus or HCV-infected patients b efore chemotherapy for hematological malignancies, it is recommended that H BV-DNA should be tested by PCR to detect HBV marker-negative carriers and l iver function tests should be carefully monitored.